Mylan and Biocon have agreed to accelerate introduction of adalimumab biosimilar in Europe through Mylan’s in-licensing arrangement with Fujifilm Kyowa Kirin Biologics (FKB).
The product is at an advanced stage of review and could receive approval in H2 of 2018 in Europe.
Mylan could commercialise FKB’s Adalimumab in EU. Biocon retains economic interest in the deal in line with its existing collaboration with Mylan for monoclonal antibodies.